Ion Beam Applications (IBA) has taken a minority stake acquisition in PET Net and PET Net Solutions, providers of PET radiopharmaceuticals to nuclear medicine facilities throughout Germany.

Eisais U.S. subsidiary Morphotek has acquired certain assets relating to a proprietary tumor targeting platform from TransMolecular.

Caliper Life Sciences has launched XenoLight RediJect COX-2 Probe (Fluorocoxibs), a fluorescent imaging agent for preclinical research that specifically detects the cyclooxygenase-2 (COX-2) biomarker noninvasively in live animal models as well as in ex vivo tissue analysis applications.

Nearly one year after initial findings indicated that intraoperative single-dose radiation is as effective as whole-breast radiation therapy in limiting recurrence of breast cancer in selected patients, physicians at Northwestern Memorial Hospital in Chicago are offering the condensed treatment to a select group of patients.

As physicians and policymakers gear up for healthcare reform and the elusive goal of improved outcomes at lower costs, providers and payors are increasingly looking to comparative effectiveness research to guide clinical practice and reimbursements, evidenced by a solid investment on the part of the government, argued the authors of a perspective article in the New England Journal of Medicine.

MIM Softwares MIM Symphony is available as a brachytherapy treatment planning system for permanent seed implants.

Out of a total of 769 men with prostate cancer who opted for active surveillance in lieu of treatment, nearly half did not require any treatment within 15 years, and no patients died from the disease, a study published online in the Journal of Clinical Oncology reported.

Novelos Therapeutics has completed its acquisition of Cellectar and $5.1 million financing to develop three novel cancer-targeted compounds.